1-4 of 4
Asmaa Mohammed Hamoda
Close
Sort by
Journal Articles

Pediatrics Non-Hodgkin's Lymphoma Survivors: Should We Worry about Quality of Life and Late Therapy Effects?

Azza Ali Fahmy Ayad, Reham Abdelaziz Khedr, Asmaa Mohammed Hamoda, Tamer Diab, Nahla Elnabarawy, Elhamy Rifky, Leslie E. Lehmann, Alaa M. Elhaddad
Journal: Blood
Blood (2022) 140 (Supplement 1): 3837–3838.
https://doi.org/10.1182/blood-2022-168009
Published: 2022
Journal Articles

Prognostic Significance of PD1, PD-L1 Expression , Pathological Subtypes and Metabolic Activity on 18F-FDG PET/CT in Refractory /Relapsing Pediatric Hodgkin Lymphoma

Reham Khedr, Eman Khorshed, Omneya Hassanein, Hany Abdelrahman, Madeeha Elwakil, Mohamed Zaghloul, Asmaa Mohammed Hamoda
Journal: Blood
Blood (2021) 138 (Supplement 1): 4545.
https://doi.org/10.1182/blood-2021-150262
Published: 2021
Journal Articles

Pretreatment Risk Factors Is a Strong Predictor of Outcome in Pediatric Hodgkin Lymphoma

Reham Khedr, MD, Hanaa Rashad, MD, Asmaa Mohammed Hamoda, MD PhD MSc, Madeha Elwakeel, PhD, Eman Khorshed, PhD, Mohamed Saad, Engy Mohamed, MSC, Emad Moussa
Journal: Blood
Blood (2019) 134 (Supplement_1): 5280.
https://doi.org/10.1182/blood-2019-131398
Published: 2019
Journal Articles

Using Childhood International Prognostic Scoring in Pediatric Hodgkin Lymphoma Patients Treated with ABVD Can Mitigate Use of Interim PET in LMIC

Reham Khedr, MD, Hanaa Rashad, MD, Asmaa Mohammed Hamoda, MD PhD MSc, Eman Khorshed, PhD, Madeha Elwakeel, PhD, Mohamed Saad, MD, Engy Mohamed, Emad Moussa
Journal: Blood
Blood (2019) 134 (Supplement_1): 1562.
https://doi.org/10.1182/blood-2019-132195
Published: 2019